Inovio Pharmaceuticals ((INO)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Inovio Pharmaceuticals recently updated their clinical study titled An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma. The study aims to evaluate the safety, immunogenicity, and preliminary clinical efficacy of the combination therapy in patients with advanced urothelial carcinoma, focusing on those who have progressed on or are ineligible for standard therapies.
The study tests a combination of two biological agents, INO-5401 and INO-9012, administered intramuscularly with electroporation, alongside the drug atezolizumab. This treatment is intended to enhance immune response against cancer cells.
This interventional study is non-randomized with a parallel assignment model, and it is open-label, meaning no masking is involved. The primary purpose is treatment-focused, aiming to assess the therapy’s effectiveness and safety.
The study began on May 24, 2018, with the primary completion date not specified, and the last update was submitted on July 9, 2025. These dates are crucial for tracking the study’s progress and data availability.
The completion of this study could significantly impact Inovio’s stock performance by potentially validating their therapeutic approach, which might also influence investor sentiment positively. The competitive landscape in cancer immunotherapy is intense, with numerous players, making successful outcomes critical for market positioning.
The study is ongoing, with further details available on the ClinicalTrials portal.